Vivaldi Biosciences Inc.

Vivaldi Biosciences is developing live attenuated vaccines with altered NS1, a gene critical to viral survival. The company's lead product is a seasonal influenza vaccine and it has early-stage programs in pandemic flu. Vivaldi views these flu projects as proof of concept that might enable broader applications in the hands of a larger company.